eCite Digital Repository
Evidence against a role for NLRP3-driven islet inflammation in db/db mice
Citation
Kammoun, HL and Allen, TL and Henstridge, DC and Barre, S and Coll, RC and Lancaster, GI and Cron, L and Reibe, S and Chan, JY and Bensellam, M and Laybutt, DR and Butler, MS and Robertson, AAB and O'Neill, LA and Cooper, MA and Febbraio, MA, Evidence against a role for NLRP3-driven islet inflammation in db/db mice, Molecular Metabolism, 10 pp. 66-73. ISSN 2212-8778 (2018) [Refereed Article]
![]() | PDF 1,008Kb |
Copyright Statement
Copyright 2018 The Authors. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/
DOI: doi:10.1016/j.molmet.2018.02.001
Abstract
Objectives: Type 2 diabetes (T2D) is associated with chronic, low grade inflammation. Activation of the NLRP3 inflammasome and secretion of its target interleukin-1β (IL-1β) have been implicated in pancreatic β cell failure in T2D. Specific targeting of the NLRP3 inflammasome to prevent pancreatic β cell death could allow for selective T2D treatment without compromising all IL-1β-associated immune responses. We hypothesized that treating a mouse model of T2D with MCC950, a compound that specifically inhibits NLRP3, would prevent pancreatic β cell death, thereby preventing the onset of T2D.
Methods: Diabetic db/db mice were treated with MCC950 via drinking water for 8 weeks from 6 to 14 weeks of age, a period over which they developed pancreatic β cell failure. We assessed metabolic parameters such as body composition, glucose tolerance, or insulin secretion over the course of the intervention.
Results: MCC950 was a potent inhibitor of NLRP3-induced IL-1β in vitro and was detected at high levels in the plasma of treated db/db mice. Treatment of pre-diabetic db/db mice with MCC950, however, did not prevent pancreatic dysfunction and full onset of the T2D pathology. When examining the NLRP3 pathway in the pancreas of db/db mice, we could not detect an activation of this pathway nor increased levels of its target IL-1β.
Conclusions: NLRP3 driven-pancreatic IL-1β inflammation does not play a key role in the pathogenesis of the db/db murine model of T2D.
Item Details
Item Type: | Refereed Article |
---|---|
Keywords: | db/db mice, inflammasome, interleukin-1 beta, MCC950, type 2 diabetes, antidiabetic agent, cryopyrin, insulin, unclassified drug, antidiabetic agent, anti-inflammatory agent, cryopyrin, fused heterocyclic rings |
Research Division: | Biological Sciences |
Research Group: | Biochemistry and cell biology |
Research Field: | Cell metabolism |
Objective Division: | Health |
Objective Group: | Clinical health |
Objective Field: | Clinical health not elsewhere classified |
UTAS Author: | Henstridge, DC (Dr Darren Henstridge) |
ID Code: | 133378 |
Year Published: | 2018 |
Web of Science® Times Cited: | 29 |
Deposited By: | Health Sciences |
Deposited On: | 2019-06-24 |
Last Modified: | 2022-08-29 |
Downloads: | 19 View Download Statistics |
Repository Staff Only: item control page